Further, the potential for NE inhibitors such as elafin to enhance BMPR2 signaling and target pathology driven by BMPR2 deficiency, identifies these drugs as promising novel therapies for PAH. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.